On March 9, 2021 Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, reported that the company will participate in two upcoming investor conferences (Press release, Revolution Medicines, MAR 9, 2021, View Source [SID1234576324]). Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will deliver a corporate presentation at the Oppenheimer 31st Annual Healthcare Conference and be the featured speaker in a fireside chat at the J.P. Morgan 10th Annual Napa Valley Forum.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of these events are as follows:
Oppenheimer 31st Annual Healthcare Conference
Conference Date: March 16-18, 2021
Presentation Time/Date: 1:10 – 1:40 p.m. Eastern on Tuesday, March 16, 2021
Format: Virtual conference
J.P. Morgan 10th Annual Napa Valley Forum
Conference Date: March 29-31, 2021
Fireside Chat Time/Date: 2:00 – 2:45 p.m. Eastern on Monday, March 29, 2021
Format: Virtual conference